Confirming our initial assumption that suPAR may differ across different tumor sites reflecting inherent biologic differences in aggressiveness and invasive potential, we found that patients with lung cancer have highest levels in the studied cohort, also supported by finding of PLAUR upregulation in lung and colorectal cancer compared to breast cancer. This evidence concerns the gene PLAUR and lung carcinoma.